Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 1;7:40744. doi: 10.1038/srep40744

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017, The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(a) CD spectra of BSA undergoing aggregation in the presence and in the absence of eugenol (at molar ratio of 1:400 of protein:ligand): BSA at 0 h (); BSA + eugenol at 0 h (); BSA at 90 h (); BSA + eugenol at 90 h (). (b) CD spectra of insulin undergoing aggregation in the presence and absence of eugenol (at molar ratio of 1:100 of protein:ligand): insulin at 0 h (); insulin + eugenol at 0 h (); insulin at 90 h (); insulin + eugenol at 90 h (). Insets of panel a and panel b show Thioflavin data for the respective CD samples. (c) Native gel-electrophoresis of the BSA (~5 μM) undergoing amyloid formation in the presence and in the absence of eugenol (at ~3 mM): (1) soluble BSA; (2) mature BSA aggregates; (3) BSA in the absence of eugenol at 5 h; (4) BSA in the presence of eugenol at ~5 h. (d) Native gel-electrophoresis of the insulin (~43 μM) undergoing amyloid formation in the presence and absence of eugenol at 1:150 molar ratio of insulin:inhibitor (1) soluble insulin; (2) mature insulin aggregates; (3) insulin in the absence of eugenol at ~6 h (4) insulin in the presence of eugenol at ~6 h. Uncropped native gel images are shown in Supplementary Figure S14.

Inline graphic — (a) CD spectra of BSA undergoing aggregation in the presence and in the absence of eugenol (at molar ratio of 1:400 of protein:ligand): BSA at 0 h (); BSA + eugenol at 0 h (); BSA at 90 h (); BSA + eugenol at 90 h (). (b) CD spectra of insulin undergoing aggregation in the presence and absence of eugenol (at molar ratio of 1:100 of protein:ligand): insulin at 0 h (); insulin + eugenol at 0 h (); insulin at 90 h (); insulin + eugenol at 90 h (). Insets of panel a and panel b show Thioflavin data for the respective CD samples. (c) Native gel-electrophoresis of the BSA (~5 μM) undergoing amyloid formation in the presence and in the absence of eugenol (at ~3 mM): (1) soluble BSA; (2) mature BSA aggregates; (3) BSA in the absence of eugenol at 5 h; (4) BSA in the presence of eugenol at ~5 h. (d) Native gel-electrophoresis of the insulin (~43 μM) undergoing amyloid formation in the presence and absence of eugenol at 1:150 molar ratio of insulin:inhibitor (1) soluble insulin; (2) mature insulin aggregates; (3) insulin in the absence of eugenol at ~6 h (4) insulin in the presence of eugenol at ~6 h. Uncropped native gel images are shown in Supplementary Figure S14.